Biocon gets nod to market psoriasis drug in India Drugs Controller General allows marketing of Bangalore-developed Itolizumab BS Reporter \/ Bangalore Jan 09, 2013, 00:53 IST <\/p>\n
Publicly-held biotechnology major Biocon announced on Tuesday that it has received marketing authorisation from the Drugs Controller General of India ( DCGI) for its novel biologic Itolizumab, anti CD6 molecule, for the treatment of chronic plaque psoriasis. <\/p>\n
Itolizumab is a first-in-class therapy and the second novel biologic developed by Biocon at Asias largest biotech hub in Bangalore. <\/p>\n
Commenting on this development, Kiran Mazumdar-Shaw, chairman and managing director of Biocon, said, This is our second novel biologic that we have developed in India, BioMab EGFR, an anti-cancer monoclonal antibody, being the first. This approval paves the way for us to extend clinical development for other indications like rheumatoid arthritis, multiple sclerosis and vitiligo. <\/p>\n
She added that the company will file an IND (investigational new drug) in the US shortly to embark on a global clinical development plan. She termed the approval for Itolizumab a defining moment for Biocon. <\/p>\n
Alzumab is expected to provide a safe and effective treatment option for psoriasis, a socially debilitating disease affecting two-three per cent of Indias population. The global psoriasis market size is estimated to cross $8 billion by 2016. <\/p>\n
Biocons share price dropped 2.3 per cent on the National Stock Exchange to close at Rs 294.70 per share on Tuesday. <\/p>\n
<\/p>\n
View original post here: Biocon gets nod to market psoriasis drug in India Drugs Controller General allows marketing of Bangalore-developed Itolizumab BS Reporter \/ Bangalore Jan 09, 2013, 00:53 IST Publicly-held biotechnology major Biocon announced on Tuesday that it has received marketing authorisation from the Drugs Controller General of India ( DCGI) for its novel biologic Itolizumab, anti CD6 molecule, for the treatment of chronic plaque psoriasis. Itolizumab is a first-in-class therapy and the second novel biologic developed by Biocon at Asias largest biotech hub in Bangalore Continue reading
\nBiocon gets nod to market psoriasis drug in India<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"